BANNER Study: Broadly Neutralizing Antibody VH3810109 in People With HIV Naive to Treatment

Source: CCO Independent Conference Coverage: Clinical Impact of New HIV Data From Fall 2022 Conferences*
Download Slideset
Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022
The broadly neutralizing antibody VH3810109, administered by a single IV infusion, displayed antiviral efficacy and was well tolerated in people with HIV naive to treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 135 KB
Released: November 4, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings